Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for metabolic genetic diseases, announced terms for its IPO on Friday. The Novato, CA-based company plans to raise $75 million by offering 4.8 million shares at a price range of $14 to $17. At the midpoint of the proposed range, Ultragenyx Pharmaceutical would command a market value of $436 million.
Ultragenyx Pharmaceutical, which was founded in 2010, plans to list on the NASDAQ under the symbol RARE. The company initially filed confidentially on October 4, 2013. J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal.
